Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Core Viewpoint - Bristol Myers (BMY) is focusing on its growth portfolio, including drugs like Reblozyl, to offset declining sales from legacy products, with Reblozyl's annualized sales exceeding $2.3 billion [1][8]. Group 1: Product Performance - Reblozyl is approved for treating anemia in adult patients with transfusion-dependent and non-transfusion-dependent beta thalassemia, as well as for certain myelodysplastic syndromes (MDS) [2]. - Sales in the U.S. are driven by strong demand in first-line RS-positive and RS-negative MDS-associated anemia, with international growth supported by successful launches in new markets [3]. - BMY anticipates continued growth opportunities, particularly in the RS-negative MDS indication, following positive results from an ex-U.S. Phase 2 study for alpha-thalassemia [3][4]. Group 2: Competitive Landscape - Keros Therapeutics is developing elritercept for treating cytopenias, including anemia in MDS patients, with a Phase III study currently underway [6]. - Geron Corporation's Rytelo is gaining traction in the MDS anemia market, generating $183.6 million in 2025, with expectations of $220 million to $240 million in 2026 [9]. Group 3: Financial Performance - BMY's shares have increased by 20.6% over the past year, outperforming the industry growth of 4.1% [10]. - The stock is trading at a price/earnings ratio of 10.05x forward earnings, which is lower than the large-cap pharma industry's average of 18.22x [11]. - The Zacks Consensus Estimate for BMY's 2026 EPS has risen to $6.26 from $6.08, indicating positive revisions in earnings expectations [12].